Oragenics eyes Q4 2026 readout for ONP-002 in mTBI, a trial not yet enrolling
The Phase 2a placebo-controlled study of Oragenics' intranasal ONP-002 targets a Q4 2026 final readout even though the 40-patient trial in Australia has not started recruiting.
Executive Summary
- Oragenics has guided investors to a final Phase 2a readout for its intranasal neurosteroid ONP-002 in mild traumatic brain injury in the fourth quarter of 2026, a narrowing of its earlier full-year guidance.
- The trial's own registry timeline, last updated in the spring of 2025, still shows a primary completion date that falls before the guided readout window and a status of not yet recruiting, though a later company disclosure describes patients already dosed.
- Concussion and mild traumatic brain injury remain without an FDA-approved pharmacological treatment, so a positive symptom-reduction signal from even a small pilot trial would be clinically distinctive.
- No trial in this indication shares ONP-002's target or mechanism, leaving the readout without a direct mechanistic precedent to benchmark against.
The catalyst
Oragenics, Inc. narrowed its 2026 guidance for a final data readout from ONP-002's Phase 2a trial in Australia to the fourth quarter of 2026, according to a February 9, 2026 disclosure. That refined window, October 1 through December 31, 2026, replaced an earlier guidance statement from November 2025 that had simply pointed to sometime within calendar year 2026. The trial, registered as NCT06870240, is a randomized, double-blind, placebo-controlled Phase 2a pilot testing ONP-002 against placebo in adults with mild traumatic brain injury (mTBI), with symptom reporting as the stated primary endpoint. Oragenics+1Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage ...Feb 9, 2026A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The registry gap
The trial's registry record, last modified April 4, 2025, lists a status of not yet recruiting, an anticipated enrollment of 40 patients, and a primary completion date of January 1, 2026. That primary completion date falls before the guided October-to-December 2026 readout window, a divergence between the registry timeline and the sponsor's stated guidance. A subsequent company disclosure, dated around April 20, 2026, describes two patients having received a total of eight study drug doses, indicating dosing activity beyond what the registry's last update reflects. NCT06870240+1A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage ...Feb 9, 2026
What the trial tests
The design is a small, non-registrational pilot: 40 patients randomized to ONP-002 or placebo, delivered intranasally, with safety, tolerability, pharmacokinetics, and pharmacodynamics as companion measures alongside the primary symptom-reporting endpoint. Inclusion criteria require diagnosis of mTBI by CT scan, elevated blood GFAP, Glasgow Coma Scale score above 12, and dosing within 12 hours of injury, a design built for acute-phase intervention rather than chronic management. A trial of this size and design is built to establish safety and an early efficacy signal, not to serve as a basis for regulatory filing on its own. NCT06870240A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240
The unmet need
Concussion and mild traumatic brain injury have no FDA-approved pharmacological treatment, and the company has described ONP-002 as a potential first pharmacological therapy for the condition. No competitor trial in this indication shares ONP-002's target or mechanism class; the closest trials in the same disease space test propranolol, lisdexamfetamine, inosine, amantadine, and cell therapy, all built on different mechanistic hypotheses. That mechanistic isolation means the ONP-002 readout will land without a same-mechanism precedent to benchmark its result against, whatever the result shows. OragenicsOragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage ...Feb 9, 2026
Sponsor context
Oragenics' broader trial portfolio includes one terminated study and one with an unknown registry status alongside the ONP-002 trial now in Not yet recruiting status. The company reported no protocol amendments to the ONP-002 trial's design since it was first registered in March 2025, and enrollment guidance has held flat at 40 patients. NCT06870240A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.